Literature DB >> 25336891

The role of moxonidine, a second generation centrally acting antihypertensive agent as antihypertensive therapy in the obese.

E Karlafti1, A Hatzitolios1, Ch Savopoulos1.   

Abstract

Entities:  

Keywords:  centrally acting agents; hypertension; moxonidine

Year:  2014        PMID： 25336891      PMCID： PMC4201414     

Source DB:  PubMed          Journal:  Hippokratia        ISSN： 1108-4189            Impact factor:   0.471


× No keyword cloud information.
  3 in total

1.  Standardized tests of heart rate variability: normal ranges obtained from 309 healthy humans, and effects of age, gender, and heart rate.

Authors:  M W Agelink; R Malessa; B Baumann; T Majewski; F Akila; T Zeit; D Ziegler
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

2.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redón; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

Review 3.  Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection.

Authors:  Eleni F Karlafti; Apostolos I Hatzitolios; Anastasios F Karlaftis; Maria S Baltatzi; Georgios G Koliakos; Christos G Savopoulos
Journal:  J Pharm Bioallied Sci       Date:  2013-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.